Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Standard of Care Systemic Therapies for Biliary Tract Cancers

March 8th 2023

Key opinion leaders in the field of biliary tract cancers highlight mainstay systemic therapy regimens within the treatment paradigm.

Role for Liver Transplant in Biliary Tract Cancers

March 8th 2023

A brief discussion on the continued role of liver transplant in biliary tract cancers and when it is appropriate to consider a patient for this procedure.

Dr. Ahn on the Evolution of First-line Treatment Options in HCC

March 7th 2023

Daniel H. Ahn, DO, discusses the evolution of first-line treatments in advanced hepatocellular carcinoma.

Dr. Ahn on the Selection of First-line ICI-Based Combinations in HCC

March 6th 2023

Daniel H. Ahn, DO, discusses the importance of drug toxicity when selecting between first-line immune checkpoint inhibitor–based regimens in hepatocellular carcinoma.

Other Frontline Immunotherapy-based Combinations in Advanced HCC

March 6th 2023

Expert oncologists analyze immunotherapy-based combinations in the frontline setting for patients with hepatocellular carcinoma.

Selecting the Appropriate Frontline Treatment in Advanced HCC

March 6th 2023

Experts discuss the factors they take into consideration when selecting the appropriate treatment in advanced HCC.

Liver-Directed Treatment Strategies in Biliary Tract Cancers

March 1st 2023

A comprehensive review of liver-directed therapies available to aid in the management of biliary tract cancers.

Biliary Tract Cancers: Surgical and Perioperative Treatment Strategies

March 1st 2023

Moving on to identify specific treatment modalities, panelists discuss the surgical and perioperative strategies used to manage biliary tract cancers.

FDA Grants Orphan Drug Designation to YB-200 for Hepatocellular Carcinoma

March 1st 2023

The FDA has granted an orphan drug designation to the CEACAM1/5 antibody YB-200 for the treatment of patients with hepatocellular carcinoma.

Survivin-Targeted Anticancer Vaccine Undergoes Investigation in Metastatic Neuroendocrine Neoplasms

February 28th 2023

Novel treatment options are needed in neuroendocrine tumors, and advances in immunotherapy have not been optimized in this population.

Dr. Van Cutsem on Primary Findings from the SPOTLIGHT and GLOW Trials in Metastatic Gastric Cancer

February 27th 2023

Eric Van Cutsem, MD, PhD, discusses primary efficacy and safety findings from the phase 3 SPOTLIGHT and GLOW trials investigating the monoclonal antibody zolbetuximab in metastatic gastric cancer.

Tislelizumab Plus Chemo Approved in China for PD-L1–High Advanced Gastric/GEJ Adenocarcinoma

February 27th 2023

The National Medical Products Administration of China has granted approval to tislelizumab in combination with fluoropyrimidine and platinum chemotherapy in the frontline treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with a high PD-L1 expression.

Dr. Harding on Future Directions in the Treatment of Advanced Biliary Tract Cancers

February 24th 2023

James Harding, MD, discusses future directions in the treatment of patients with advanced biliary tract cancer.

TTFields With Chemotherapy Under Investigation in Locally Advanced Pancreatic Cancer

February 23rd 2023

Tumor treating fields concomitant with gemcitabine and nab-paclitaxel is being compared with chemotherapy alone in the frontline treatment of patients with aggressive, locally advanced pancreatic cancer as part of the phase 3 PANOVA-3 trial.

Dr. Harding on the Evolution of Frontline Chemotherapy Approaches in Advanced Biliary Tract Cancer

February 23rd 2023

James Harding, MD, discusses key trials contributing to the evolution of frontline chemoimmunotherapy approaches in advanced biliary tract cancer.

EU Approves Durvalumab/Tremelimumab Combo for Advanced Lung, Liver Cancers

February 22nd 2023

The European Union has approved durvalumab plus tremelimumab-actl for first-line treatment of advanced or unresectable hepatocellular carcinoma and in combination with platinum-based chemotherapy in metastatic non–small cell lung cancer, according to a news release from AstraZeneca.

Advent of Molecular Testing in Biliary Tract Cancers

February 22nd 2023

Key opinion leaders review the advent of molecular testing in biliary tract cancers and consider its impact on informing treatment decisionmaking.

Optimizing the Staging of Biliary Tract Cancers

February 22nd 2023

Focused conversation on the optimal workup and staging of biliary tract cancers within the current paradigm.

Zanidatamab Plus Chemo Displays Early Activity in HER2+ Metastatic Gastroesophageal Adenocarcinoma

February 22nd 2023

The combination of zanidatamab and standard chemotherapy demonstrated activity when used as a first-line treatment for patients with HER2-positive metastatic or advanced gastroesophageal adenocarcinoma.

HIMALAYA Study: Durvalumab + Tremelimumab in First-Line Treatment of Advanced HCC

February 20th 2023

Panelists review the HIMALAYA study, investigating durvalumab plus tremelimumab in patients with advanced HCC.